BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Mr. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer.

“Gary brings dynamic experience in pharmaceutical compliance, legal operations, and executive leadership,” said Sandy Macrae, Sangamo's Chief Executive Officer. “We are pleased Gary is joining Sangamo and look forward to his contributions as Sangamo continues to grow as a clinical stage development company, and eventually into commercialization.”

Mr. Loeb has over 20 years of experience in biotechnology and pharmaceutical law, compliance, intellectual property, litigation, human resources, regulatory, and facilities. Before joining Sangamo, he served as General Counsel, Corporate Secretary, and Chief Compliance Officer at Achaogen, an anti-infectives company. At Achaogen, Mr. Loeb was a member of the Executive Team and the first full-time in-house attorney, where he built the legal and compliance teams. Before Achaogen, Mr. Loeb worked in roles of increasing responsibility at Counsyl, a genetic screening company, Amyris, Inc., and Genentech.

Mr. Loeb received his B.S. and B.A. degrees from Stanford University and his J.D. from Columbia Law School.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com